Elite in Hodgkin Lymphoma

Aspasia Stamatoullas

Rouen, FR 
Elite in Hodgkin Lymphoma
Rouen, FR 
OverviewLocationsClinical Research

Overview

Aspasia Stamatoullas practices in Rouen, France. Ms. Stamatoullas is rated as an Elite expert by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS), Primary Mediastinal B-Cell Lymphoma (PMBCL), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 95 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 40 articles and participated in 3 clinical trials in the study of Hodgkin Lymphoma.

Gender
Female

Locations

Rouen, France
Other Locations
Sophie Park, Grenoble, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: AG-221 IDH2 Inhibitor
Study Phase: Phase 2
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: AG-120
Study Phase: Phase 2
A Phase II Prospective Study GFM-DACORAL-DLI ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
A Phase II Prospective Study GFM-DACORAL-DLI ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Enrollment Status: Completed
Publish Date: May 14, 2025
Intervention Type: Other, Drug
Study Phase: Phase 2
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Drug
Study Drug: EPREX Erythropoietin
Study Phase: Phase 3
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Other
Study Phase: Not Applicable
Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.
Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Brentuximab
Study Phase: Phase 2
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Drugs: Decitabine, Hydroxyurea
Study Phase: Phase 3
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Enrollment Status: Completed
Publish Date: July 26, 2021
Intervention Type: Drug, Radiation
Study Drugs: Brentuximab, Cyclophosphamide, Adriamycin, Oncovin, Bleomycin, Etoposide, Procarbazine, Prednisone, Filgrastim
Study Phase: Phase 2
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
Enrollment Status: Completed
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin
A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Enrollment Status: Completed
Publish Date: December 06, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

95 Total Publications

Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.
Efficacy and safety of luspatercept with or without erythropoiesis-stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real-life study by the GFM.
Journal: British journal of haematology
Published: March 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Stamatoullas's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile